ERCC1 expression can predict survival in patients with advanced head and neck cancer
This article has no abstract so we have provided the first paragraph of the full text.
Expression of the excision repair cross complementation group 1 (ERCC1) enzyme has been linked to platinum resistance in various cancer cell lines. ERCC1 expression was shown to predict survival benefit of cisplatin-based chemotherapy in patients with non-small-cell lung cancer. A study by Handra-Luca et al. has evaluated the role of ERCC1 in tumor response and survival in patients with head and neck cancer treated with cisplatin-based chemotherapy.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.